SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years.

Today in BMC Medicine, researchers in Catalonia, Spain, estimate that 23% of adult COVID-19 survivors develop long COVID, ...

Five years after the World Health Organization declared a global pandemic, there has been progress — and backsliding in the ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. Long ...

SARS-CoV-2 between 2021 and 2023 developed long-COVID, and in more than half of them the symptoms persisted for two years ...